Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

VIJAY K GUNUGANTI

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1073535076
CMS profile
184290
Location
SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$169,902.16

194 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 3 of 4; records 101–150 of 194 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

VIJAY K GUNUGANTI

NPI 1073535076 · CMS profile ID 184290

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 194 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1073535076?year=2021&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
VIJAY K GUNUGANTI, NPI 1073535076, CMS profile ID 184290. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 194 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1073535076?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). VIJAY K GUNUGANTI, NPI 1073535076, CMS profile ID 184290. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 194 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1073535076?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
VIJAY K GUNUGANTI, NPI 1073535076, CMS profile ID 184290, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 194 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1073535076?year=2021&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

194 matching records · $169,902.16 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 194 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 194.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Biotech, Inc. $1,000.0007/01/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788996285 CMS
Rigel Pharmaceuticals, Inc. $10.0207/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 854325743 CMS
E.R. Squibb & Sons, L.L.C. $4,505.0006/29/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783425053 CMS
E.R. Squibb & Sons, L.L.C. $4,505.0006/29/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783425109 CMS
Eisai Inc. $124.7006/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833752383 CMS
E.R. Squibb & Sons, L.L.C. $124.9906/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783425057 CMS
Eisai Inc. $19.0206/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 817976649 CMS
Janssen Pharmaceuticals, Inc $1,000.0006/25/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788996345 CMS
Janssen Pharmaceuticals, Inc $1,000.0006/25/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788996347 CMS
AstraZeneca Pharmaceuticals LP $450.0006/23/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834349187 CMS
Rigel Pharmaceuticals, Inc. $101.0906/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 854329091 CMS
E.R. Squibb & Sons, L.L.C. $4,505.0006/22/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783425065 CMS
E.R. Squibb & Sons, L.L.C. $58.9206/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783425073 CMS
E.R. Squibb & Sons, L.L.C. $24.9106/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783425173 CMS
Amgen Inc. $96.0406/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826451995 CMS
PFIZER INC. $11.0606/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832660549 CMS
E.R. Squibb & Sons, L.L.C. $121.8406/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783425175 CMS
Rigel Pharmaceuticals, Inc. $8.3106/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 854325267 CMS
AstraZeneca Pharmaceuticals LP $250.0006/15/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834317553 CMS
E.R. Squibb & Sons, L.L.C. $127.3206/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783425055 CMS
Janssen Pharmaceuticals, Inc $1,000.0006/14/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788996341 CMS
Janssen Pharmaceuticals, Inc $1,000.0006/14/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788996343 CMS
AstraZeneca Pharmaceuticals LP $12.7806/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834334649 CMS
E.R. Squibb & Sons, L.L.C. $1,400.0006/08/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783425049 CMS
Janssen Pharmaceuticals, Inc $13.0106/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788996425 CMS
AstraZeneca Pharmaceuticals LP $2,150.0006/03/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834342769 CMS
AstraZeneca Pharmaceuticals LP $1,050.0006/03/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834351467 CMS
E.R. Squibb & Sons, L.L.C. $121.0106/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783425063 CMS
Gilead Sciences, Inc. $11.9206/01/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845873699 CMS
E.R. Squibb & Sons, L.L.C. $4,505.0005/25/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783425043 CMS
E.R. Squibb & Sons, L.L.C. $4,505.0005/25/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783425045 CMS
AstraZeneca Pharmaceuticals LP $124.9905/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834338041 CMS
AstraZeneca Pharmaceuticals LP $2,150.0005/17/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834319325 CMS
E.R. Squibb & Sons, L.L.C. $1,875.0005/17/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783425029 CMS
E.R. Squibb & Sons, L.L.C. $140.7005/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783425037 CMS
Rigel Pharmaceuticals, Inc. $8.6605/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 854325495 CMS
E.R. Squibb & Sons, L.L.C. $9.7405/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783425039 CMS
Janssen Pharmaceuticals, Inc $1,000.0005/10/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788996339 CMS
PFIZER INC. $14.3805/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832646967 CMS
E.R. Squibb & Sons, L.L.C. $124.9905/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783425041 CMS
E.R. Squibb & Sons, L.L.C. $4,505.0005/04/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783425035 CMS
E.R. Squibb & Sons, L.L.C. $16.1305/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783425023 CMS
E.R. Squibb & Sons, L.L.C. $4.5405/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783425025 CMS
Janssen Biotech, Inc. $1,000.0005/03/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788996287 CMS
Janssen Pharmaceuticals, Inc $1,000.0005/03/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788996349 CMS
E.R. Squibb & Sons, L.L.C. $63.5104/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783425047 CMS
AstraZeneca Pharmaceuticals LP $117.2204/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834346929 CMS
Rigel Pharmaceuticals, Inc. $9.3504/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 854325895 CMS
AstraZeneca Pharmaceuticals LP $1,050.0004/18/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834350503 CMS
Janssen Pharmaceuticals, Inc $13.4404/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788996429 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $116,650.89 121
PY2020 $134,478.28 162
PY2021 $169,902.16 194
PY2022 $256,632.86 275
PY2023 $289,496.21 249
PY2024 $215,084.68 178
PY2025 $333,756.56 308

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $94,223.91 28
PY2024 Principal investigator $222,904.33 22
PY2023 Principal investigator $31,006.10 13
PY2022 Principal investigator $30,867.56 19
PY2021 Principal investigator $97,950.03 80
PY2020 Principal investigator $165,343.50 296
PY2019 Principal investigator $18,926.62 5

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

28 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $4,346.00 12/01/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175407441
Principal investigator 1 Janssen Research & Development, LLC $299.00 11/24/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175406957
Principal investigator 1 Janssen Research & Development, LLC $476.00 11/07/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175407222
Principal investigator 1 GlaxoSmithKline, LLC. $1,125.00 10/28/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCHLLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S No dispute reported 06/30/2026 1192107688
Principal investigator 1 Janssen Research & Development, LLC $291.00 09/22/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175408188
Principal investigator 1 GlaxoSmithKline, LLC. $1,125.00 08/22/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCHLLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S No dispute reported 06/30/2026 1192107683
Principal investigator 1 Janssen Research & Development, LLC $649.00 07/28/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175406963
Principal investigator 1 Janssen Research & Development, LLC $1,547.00 07/25/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175404919
Principal investigator 1 Janssen Research & Development, LLC $5,142.00 07/07/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175407950
Principal investigator 1 GlaxoSmithKline, LLC. $1,125.00 05/30/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCHLLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S No dispute reported 06/30/2026 1192107676
Principal investigator 1 GlaxoSmithKline, LLC. $1,125.00 05/26/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCHLLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S No dispute reported 06/30/2026 1192107693
Principal investigator 1 GlaxoSmithKline, LLC. $2,945.88 05/26/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCHLLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S No dispute reported 06/30/2026 1192110043
Principal investigator 1 Janssen Research & Development, LLC $299.00 05/22/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175405109
Principal investigator 1 Janssen Research & Development, LLC $1,697.00 05/22/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175406862
Principal investigator 1 Janssen Research & Development, LLC $1,547.00 05/22/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175407490
Principal investigator 1 Janssen Research & Development, LLC $1,907.00 05/22/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175408215
Principal investigator 1 AstraZeneca Pharmaceuticals LP $10,500.00 05/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A Randomized 2-cohort Double-blind Placebo-controlled Phase III Study of AZD5305 in Combination with Physicians Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer EvoPAR-Prostate01 No dispute reported 06/30/2026 1185540701
Principal investigator 1 AstraZeneca Pharmaceuticals LP $5,150.00 04/30/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY, PA
A Randomized 2-cohort Double-blind Placebo-controlled Phase III Study of AZD5305 in Combination with Physicians Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer EvoPAR-Prostate01 No dispute reported 06/30/2026 1185540697
Principal investigator 1 Janssen Research & Development, LLC $4,100.00 04/03/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175408311
Principal investigator 1 Janssen Research & Development, LLC $4,346.00 03/07/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175407310
Principal investigator 1 Janssen Research & Development, LLC $1,907.00 02/17/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175404855
Principal investigator 1 Janssen Research & Development, LLC $1,547.00 02/17/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175405184
Principal investigator 1 Janssen Research & Development, LLC $1,697.00 02/17/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175406252
Principal investigator 1 Janssen Research & Development, LLC $299.00 02/17/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175407227
Principal investigator 1 GlaxoSmithKline, LLC. $1,125.00 02/07/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCHLLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S No dispute reported 06/30/2026 1192107700
Principal investigator 1 AstraZeneca Pharmaceuticals LP $7,600.00 01/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized 2-cohort Double-blind Placebo-controlled Phase III Study of AZD5305 in Combination with Physicians Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer EvoPAR-Prostate01 No dispute reported 06/30/2026 1185540699
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,810.00 01/15/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY SOUTHWEST FORT WORTH
A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) No dispute reported 06/30/2026 1185540695
Principal investigator 1 AstraZeneca UK Limited $28,497.03 01/14/2025 Non-covered Recipient Entity
THE US ONCOLOGY NETWORK
A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) No dispute reported 06/30/2026 1185540693